Does androgen deprivation therapy protect against severe complications from COVID-19?

Ann Oncol. 2020 Oct;31(10):1419-1420. doi: 10.1016/j.annonc.2020.06.023. Epub 2020 Jul 9.

Authors

V G Patel¹, X Zhong², B Liaw¹, D Tremblay¹, C-K Tsao¹, M D Galsky¹, W K Oh³

Affiliations

¹ Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
² Department of Population Health and Policy, Icahn School of Medicine at Mount Sinai, New York, USA.
³ Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: william.oh@mssm.edu.

No abstract available

Publication types

Letter
Comment

MeSH terms

Androgen Antagonists
Betacoronavirus
COVID-19
Coronavirus Infections*
Humans
Male
Pandemics*
Pneumonia, Viral*
Prostatic Neoplasms / epidemiology*
SARS-CoV-2
Severe Acute Respiratory Syndrome*

Substances

Androgen Antagonists